SecurityLJPC / La Jolla Pharmaceutical Co. (503459604)
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Common Stock Shares Outstanding26,154,439 shares (as of 2018-03-31)
Total Insiders15
Total Directors6
Total Officers5

Stock Insider Trading (from SEC Form 4)

LJPC / La Jolla Pharmaceutical Co. Insider Trades

La Jolla Pharmaceutical Co. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

LJPC / La Jolla Pharmaceutical Co. insiders include Johnson Craig A, Chawla Lakhmir S, EDELMAN JOSEPH, and TANG KEVIN C, CARVER JENNIFER, Zarrabian Saiid TANG CAPITAL PARTNERS LP, PERCEPTIVE LIFE SCIENCES MASTER FUND LTD, MULROY DENNIS, PERCEPTIVE ADVISORS LLC, Rosen Robert, TANG CAPITAL MANAGEMENT LLC, Douglass Laura L., TIDMARSH GEORGE F, Rolke James, .

Insider Roster

Insider Dir Off 10% Shares Owned
Douglass Laura L. Director
X 500
PERCEPTIVE ADVISORS LLC 10% Owner
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD 10% Owner
EDELMAN JOSEPH 10% Owner
X 4,313,611
TANG CAPITAL MANAGEMENT LLC 10% Owner
TANG KEVIN C Director, 10% Owner
TANG CAPITAL PARTNERS LP 10% Owner
X 4,138,893
TANG CAPITAL PARTNERS LP 10% Owner
TANG CAPITAL MANAGEMENT LLC 10% Owner
TANG KEVIN C Director, 10% Owner
X 3,630,419
CARVER JENNIFER Chief Operating Officer
X 5,500
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD 10% Owner
EDELMAN JOSEPH 10% Owner
PERCEPTIVE ADVISORS LLC 10% Owner
X 3,563,611
Chawla Lakhmir S Chief Medical Officer
X
MULROY DENNIS Chief Financial Officer
X
TIDMARSH GEORGE F President, CEO & Secretary, Director
X X
Rolke James Chief Scientific Officer
X
Johnson Craig A Director
X
Rosen Robert Director
X
TANG KEVIN C Director, 10% Owner
X X
Zarrabian Saiid Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2018-05-30 4 Douglass Laura L. M D 6 500 500
2018-03-15 4 PERCEPTIVE ADVISORS LLC P I 29.50 700,000 4,313,611 127,251,524
2018-03-15 4 TANG KEVIN C By LP P I 29.50 508,474 4,138,893 122,097,344
2018-03-02 4 TANG KEVIN C By LP P I 30.4435 10,000 3,630,419 110,522,661
2018-02-28 4 TANG KEVIN C By LP P I 30.154 10,000 3,620,419 109,170,115
2018-02-28 4 TANG KEVIN C By LP P I 30.1171 10,000 3,610,419 108,735,350
2018-02-28 4 TANG KEVIN C By LP P I 29.5381 10,000 3,600,419 106,349,536
2018-02-23 4 CARVER JENNIFER P D 32.475 1,000 5,500 178,612
2018-02-27 4 TANG KEVIN C By LP P I 30.6037 10,000 3,590,419 109,880,106
2018-02-27 4 TANG KEVIN C By LP P I 30.688 10,000 3,580,419 109,875,898
2018-02-27 4 TANG KEVIN C By LP P I 30.8725 10,000 3,570,419 110,227,761
2018-02-27 4 TANG KEVIN C By LP P I 30.8796 10,000 3,560,419 109,944,315
2018-02-27 4 TANG KEVIN C By LP P I 30.5714 10,000 3,550,419 108,541,279
2018-02-27 4 TANG KEVIN C By LP P I 32.1728 10,000 3,540,419 113,905,192
2018-02-27 4 TANG KEVIN C By LP P I 32.6982 9,000 3,530,419 115,438,347
2018-02-26 4 TANG KEVIN C By LP P I 32.502 1,000 3,521,419 114,453,160
2018-02-26 4 TANG KEVIN C By LP P I 32.4821 10,000 3,520,419 114,350,602
2018-02-26 4 TANG KEVIN C By LP P I 32.916 10,000 3,510,419 115,548,952
2018-02-23 4 TANG KEVIN C By LP P I 32.3046 10,000 3,500,419 113,079,636
2018-02-23 4 TANG KEVIN C By LP P I 32.58 20,000 3,490,419 113,717,851
2018-02-23 4 TANG KEVIN C By LP P I 32.4186 10,000 3,470,419 112,506,125
2018-02-23 4 TANG KEVIN C By LP P I 31.9442 10,000 3,460,419 110,540,317
2018-02-23 4 TANG KEVIN C By LP P I 31.5413 10,000 3,450,419 108,830,701
2018-02-15 4 PERCEPTIVE ADVISORS LLC P I 32.42 50,000 3,613,611 117,153,269
2018-02-14 4 PERCEPTIVE ADVISORS LLC P I 32.69 100,000 3,563,611 116,494,444
2018-02-13 4 PERCEPTIVE ADVISORS LLC P I 32.75 75,000 3,463,611 113,433,260
2017-12-29 4 Douglass Laura L. S D 32.3208 -10,000 0
2017-12-29 4 Douglass Laura L. M D 6 4,000 10,000
2017-12-29 4 Douglass Laura L. M D 10.84 6,000 6,000
2017-12-27 4 CARVER JENNIFER P D 33.215 1,000 4,500 149,468
2017-03-23 4 TANG KEVIN C By LP P I 33.50 149,254 3,440,419 115,254,036
2017-03-02 4 CARVER JENNIFER P D 34.435 300 3,500 120,522
2017-03-02 4 CARVER JENNIFER P D 34.4455 300 3,200 110,226
2017-03-02 4 CARVER JENNIFER P D 34.489 400 2,900 100,018
2017-03-03 4 TIDMARSH GEORGE F P D 34.15 1,000 1,354,086 46,242,037
2017-03-02 4 TIDMARSH GEORGE F P D 34.1773 2,000 1,353,086 46,244,826
2017-03-03 4 Chawla Lakhmir S P D 34.4799 1,000 2,085 71,891
2017-03-02 4 Chawla Lakhmir S P D 35.3299 600 1,085 38,333
2017-03-02 4 TANG KEVIN C By LP P I 34.6384 100,000 3,291,165 114,000,690
2017-03-03 4 MULROY DENNIS P D 33.95 500 500 16,975
2016-12-28 4 TIDMARSH GEORGE F G D -74,000 1,373,086
2016-09-13 4 TANG KEVIN C By LP P I 20.2769 16,448 3,191,165 64,706,934
2016-09-12 4 TANG KEVIN C By LP P I 19.9179 22,587 3,174,717 63,233,696
2016-09-09 4 TANG KEVIN C By LP P I 19.7197 100,000 3,152,130 62,159,058
2016-03-04 4 TANG KEVIN C By LP P I 19.8464 20,000 3,052,130 60,573,793
2016-03-01 4 TIDMARSH GEORGE F P D 16.50 1,000 2,871,172 47,374,338
2016-03-01 4 TIDMARSH GEORGE F P D 16.64 1,000 2,871,172 47,776,302
2016-03-03 4 TANG KEVIN C By LP P I 18.9096 13,500 29,583,772 559,417,295
2016-03-03 4 TANG KEVIN C By LP P I 18.7244 20,000 29,583,772 553,938,380
2016-03-03 4 TANG KEVIN C By LP P I 18.5453 20,000 29,583,772 548,639,927
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Related News Stories

2 Stable and 2 Speculative Biotech Stocks to Buy | InvestorPlace

2018-06-15 investorplace
Biotech stocks represent a peculiar conundrum. On one hand, they are scientifically the most exciting investment sector. Successes here could spark revolutionary therapies that could end or at least alleviate human suffering. But the industry is heavily marked with failures and agonizing disappointments. (7-1)

Your Daily Pharma Scoop: Abeona Update, Alexion Data, Solid Biosciences Setback

2018-03-16 seekingalpha
Today we will discuss Abeona Therapeutics (ABEO) after the company announced that it has nabbed a Rare Pediatric Disease designation from the FDA for ABO-202 for the treatment of CLN1 disease, which is a rare inherited disorder of the nervous system. (159-4)